Rakovina Therapeutics Receives Buy Rating from First Berlin Equity Research

On April 2, 2025, First Berlin Equity Research initiated coverage on Rakovina Therapeutics Inc., assigning a buy rating with a target price of CAD 0.40. This preclinical-stage biotech company focuses on DNA Damage Response (DDR) pathways, using artificial intelligence to develop next-generation cancer treatments.

Rakovina targets the PARP and ATR mechanisms, well-established in oncology. Their next-generation PARP inhibitors (PARPis) aim to improve upon first-generation PARPis by enhancing brain penetration and reducing toxicity, potentially offering safer, more effective treatments, including combination therapies.

The PARPi market is expected to expand significantly, from USD 4 billion in 2024 to USD 16 billion by 2034. Rakovina is strategically positioned to capitalize on this growth, given the biotech's focused pipeline and the increasing interest from Big Pharma companies.